NCT03961672View on ClinicalTrials.gov

Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

May 13, 2020

Primary Completion Date

July 31, 2023

Study Completion Date

November 5, 2025

Conditions
Recurrent Chronic Lymphocytic LeukemiaRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic LeukemiaRefractory Small Lymphocytic Lymphoma
Interventions
DRUG

Duvelisib

Given PO

Trial Locations (3)

91010

City of Hope Medical Center, Duarte

97239

OHSU Knight Cancer Institute, Portland

02215

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER